

Reference Data

2nd Quarter - Fiscal Year 2021
(April 1, 2021 to September 30, 2021)

Consolidated Earnings

• Consolidated Financial Data	p. 1
• Consolidated Balance Sheets	p. 2
• Consolidated P/L Statement	p. 3
• Consolidated Sales Breakdown by Segment/Category	p. 4
• Consolidated Operating Profit by Segment	p. 4
• Consolidated Sales -	
Leading Brands of Self-Medication Operations	
Sales by Region	p. 5
• Consolidated Sales -	
Leading Products of Prescription Pharmaceutical Operations	p. 6
• Capital Expenditure	p. 7
• Depreciation and Amortization	p. 7
• R&D Expenses	p. 7
• Major Subsidiaries and Affiliates	p. 8
• Shareholders Information	p.9
• Prescription Pharmaceutical Operations:	
New Drug Development-Taisho Pharmaceutical	p. 10
• Launch of New Products	p. 12

Taisho Pharmaceutical Holdings Co.,Ltd.

Consolidated Financial Data

(Millions of yen)

	March 2021(FY2020)***				March 2022(FY2021)***		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Net sales	71,532	138,851	203,287	267,920	63,884	130,161	269,000
(YOY%)	-	-	-	-	(-14.8%)	(-6.3%)	(+0.4%)
Self-Medication operations	54,178	108,910	161,416	217,056	53,623	110,598	231,100
Prescription Pharmaceutical operations	17,353	29,940	41,870	50,863	10,260	19,562	37,900
Gross profit on sales*	44,231	87,286	126,993	163,815	39,739	78,523	165,500
Selling, general and administrative expenses	34,842	70,991	106,129	143,849	37,063	76,210	151,000
Research and development expenses	4,209	9,429	14,354	20,251	4,629	9,673	21,600
(% Sales)	(5.9%)	(6.8%)	(7.1%)	(7.6%)	(7.2%)	(7.4%)	(8.0%)
Advertising expenses	6,107	11,905	17,645	25,017	7,029	15,325	32,000
Sales promotion expenses	3,561	7,546	11,313	15,255	3,421	6,932	13,100
Personnel expenses	8,201	16,522	25,039	32,953	9,701	18,353	33,100
Operating Profit	9,389	16,295	20,864	19,965	2,676	2,313	14,500
(YOY%)	(+12.8%)	(+12.2%)	(+22.1%)	(-5.5%)	(-71.5%)	(-85.8%)	(-27.4%)
Earnings before the amortization of goodwill and trademarks	12,399	22,233	29,839	32,008	5,756	8,563	26,400
Ordinary Profit	11,117	18,859	24,742	25,946	4,033	4,223	18,500
(YOY%)	(+45.3%)	(+29.1%)	(+22.0%)	(+6.0%)	(-63.7%)	(-77.6%)	(-28.7%)
Profit attributable to owners of parent	6,064	11,294	14,235	13,316	1,179	2,908	10,500
(YOY%)	(-44.9%)	(-23.6%)	(-20.0%)	(-34.0%)	(-80.5%)	(-74.3%)	(-21.1%)
Comprehensive income	3,537	10,802	16,541	28,920	6,953	12,965	-
(YOY%)	(-33.3%)	(+36.4%)	(+88.0%)	(+241.4%)	(+96.6%)	(+20.0%)	-
Basic EPS (yen)	75.98	141.51	178.35	166.84	14.78	35.95	131.45
Diluted EPS (yen)	75.89	141.34	178.12	166.63	14.75	35.90	131.29
BPS (yen)	8,862.95	8,949.88	8,967.90	9,129.95	9,131.84	9,085.03	9,158.01
Dividend per share (yen)	-	50.00	-	100.00	-	50.00	100.00
Payout ratio	-	-	-	59.9%	-	-	76.1%
Capital expenditure	2,659	5,701	8,182	15,121	1,779	7,749	17,600
Depreciation and amortization	3,673	7,206	10,925	14,700	3,508	7,347	14,000
Total assets	858,187	861,043	861,329	876,923	877,471	885,595	879,000
Shareholders' equity	736,944	744,157	745,217	758,406	757,842	763,880	761,000
Return on equity (%)**	-	-	-	1.9%	-	-	1.4%
Return on assets (%)**	-	-	-	1.5%	-	-	1.2%
Equity ratio (%)	82.4%	83.0%	83.1%	83.1%	83.1%	84.1%	83.2%
Overseas sales	27,063	47,518	67,833	92,607	24,824	47,729	98,400
Overseas sales ratio (% of total sales)	36.1%	32.6%	31.7%	32.8%	38.9%	36.7%	36.6%
Number of employees	9,356	9,304	9,234	9,195	9,254	9,203	-

* After provision/reversal of reserve for returned unsold goods

** Average of the beginning and year-end balance of shareholders' equity / total assets

*** Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

<Reference>

• E=Estimates

• Full year forecasts for the fiscal year ending March 31, 2022 were announced on May 14, 2021.

Consolidated Balance Sheets

(Millions of yen)

	End of FY2020		End of FY2021 2Q*		change	
	(March 31, 21)	% total	(September 30, 21)	% total		
(Assets)						
I Current assets:	357,731	40.8%	361,527	40.8%	+3,796	
Cash and deposits	250,178		254,232		+4,054	
Notes and accounts receivable-trade	51,609		48,929		-2,679	
Marketable securities	4,017		4,008		-8	
Inventories	46,384		44,292		-2,092	
Other	5,540		10,063		+4,523	
II Fixed assets:	519,192	59.2%	524,068	59.2%	+4,876	
(1) Tangible fixed assets:	113,194	(12.9%)	116,293	(13.1%)	+3,099	
Buildings and structures	51,876		50,798		-1,077	
Machinery, equipment and vehicles	14,494		14,750		+256	
Land	37,429		37,469		+40	
Other	9,393		13,273		+3,880	The new Biofermin Pharmaceutical Co., Ltd. factory and others
(2) Intangible fixed assets:	216,532	(24.7%)	219,748	(24.8%)	+3,215	
Goodwill	128,612		129,670		+1,058	Change of the rate of exchange
Sales rights	453		409		-43	
Trademarks	69,258		69,894		+636	Change of the rate of exchange
Software	10,341		11,711		+1,370	
Other	7,867		8,061		+193	
(3) Investments and other assets:	189,464	(21.6%)	188,026	(21.2%)	-1,437	
Investment securities	156,055		154,118		-1,936	Impact of the sale of stock and other factors
Shares of subsidiaries and affiliates	12,261		12,487		+225	
Net defined benefit assets	10,620		10,904		+283	
Deferred tax assets	8,892		8,688		-203	
Other	1,634		1,827		+192	
Total assets	876,923	100.0%	885,595	100.0%	+8,672	
(Liabilities)						
I Current liabilities:	57,666	6.6%	61,719	7.0%	+4,053	
Notes and accounts payable-trade	14,672		13,917		-754	
Accounts payable	16,068		17,757		+1,688	
Accrued income taxes	3,275		2,168		-1,106	
Refund liability	-		6,277		+6,277	Application of the accounting standard for revenue recognition
Provision for bonuses	3,523		5,267		+1,744	
Other	20,126		16,331		-3,795	
II Long-term liabilities:	60,849	6.9%	59,995	6.8%	-854	
Net defined benefit liabilities	21,321		21,504		+183	
Deferred taxes liabilities	32,747		31,013		-1,733	
Other	6,780		7,477		+696	
Total liabilities	118,516	13.5%	121,715	13.7%	+3,198	
(Net assets)						
I Shareholders' equity	697,598	79.6%	705,854	79.7%	+8,255	
Common stock	30,000		30,000		-	
Capital surplus	12		-		-12	
Retained earnings	703,036		696,872		-6,163	Payment of dividend
Treasury stock	-35,450		-21,018		+14,432	
II Accumulated other comprehensive income	31,105	3.5%	39,005	4.4%	+7,899	
Valuation difference on securities	30,026		28,636		-1,390	
Foreign currency translation adjustment	-235		9,107		+9,343	Change of the rate of exchange
Remeasurements of defined benefit plans	1,315		1,261		-53	
III Share acquisition rights	801	0.1%	755	0.1%	-45	
IV Non-controlling interests	28,900	3.3%	18,264	2.1%	-10,636	
Total net assets	758,406	86.5%	763,880	86.3%	+5,473	
Total liabilities and net assets	876,923	100.0%	885,595	100.0%	+8,672	

* The accounting standard for revenue recognition has been applied from FY2021 onwards.

Consolidated P/L Statement

(Millions of yen)

	FY2020		FY2021		YOY change	
	2Q	% total	2Q	% total		
Net sales	138,851	100.0%	130,161	100.0%	-8,690	
Cost of sales	51,608	37.2%	51,637	39.7%	+28	
Gross profit on sales	87,243	62.8%	78,523	60.3%	-8,719	
Provision for sales returns	-43		-		+43	
Gross profit	87,286	62.9%	78,523	60.3%	-8,763	
Selling, general and administrative expenses	70,991	51.1%	76,210	58.6%	+5,219	
Research and development expenses	9,429		9,673		+243	
Advertising expenses	11,905		15,325		+3,419	
Sales promotion expenses	7,546		6,932		-614	
Personnel expenses	16,522		18,353		+1,830	
Other	25,586		25,926		+339	
Operating Profit	16,295	11.7%	2,313	1.8%	-13,982	
Non-operating income	2,772	2.0%	2,391	1.8%	-380	
Non-operating expenses	208	0.1%	481	0.4%	+273	
Ordinary Profit	18,859	13.6%	4,223	3.2%	-14,636	
Extraordinary income	3	0.0%	2,125	1.6%	+2,121	FY2021: Sale of investment securities +2,086
Extraordinary losses	470	0.3%	79	0.1%	-390	
Profit before income taxes and minority interests	18,393	13.2%	6,269	4.8%	-12,124	
Income taxes	5,983	4.3%	2,320	1.8%	-3,662	
Profit	12,409	8.9%	3,948	3.0%	-8,461	
Profit attributable to non-controlling interests	1,115	0.8%	1,040	0.8%	-74	
Profit attributable to owners of parent	11,294	8.1%	2,908	2.2%	-8,386	

* Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2021(FY2020)				March2022(FY2021)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Self-Medication operations (YOY%)	54,178 -	108,910 -	161,416 -	217,056 -	53,623 (-1.0%)	110,598 (+1.5%)	231,100 (+6.5%)
Japan	27,009	60,598	92,383	122,977	28,873	62,832	131,300
Overseas	26,692	47,105	67,152	91,697	24,270	46,735	98,000
Other	476	1,206	1,881	2,382	479	1,030	1,800
Prescription Pharmaceutical operations (YOY%)	17,353 -	29,940 -	41,870 -	50,863 -	10,260 (-40.9%)	19,562 (-34.7%)	37,900 (-25.5%)
Ethical drugs	16,961	29,388	41,047	49,965	9,480	18,171	36,800
Other	392	551	823	898	780	1,391	1,100
Total	71,532	138,851	203,287	267,920	63,884	130,161	269,000

* Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

Consolidated Operating Profit by Segment

(Millions of yen)

	March 2021(FY2020)**				March2022(FY2021)**		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Self-Medication operations (YOY%)	5,483 (-22.0%)	12,526 (-2.9%)	16,855 (+23.6%)	19,395 (+3.7%)	3,112 (-43.2%)	3,994 (-68.1%)	20,500 (+5.7%)
Earnings before the amortization of goodwill and trademarks	8,494	18,464	25,830	31,438	6,192	10,245	32,400
Prescription Pharmaceutical operations (YOY%)	4,466 (+178.1%)	4,857 (+104.0%)	5,496 (+15.9%)	2,495 (-39.8%)	15 (-99.7%)	-721 (+0.0%)	-4,000 (-)
Other* (YOY%)	-561 (-)	-1,087 (-)	-1,488 (-)	-1,925 (-)	-451 (-)	-959 (-)	-2,000 (-)
Total	9,389	16,295	20,864	19,965	2,676	2,313	14,500

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

** Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

Consolidated Sales - Leading Brands of Self-Medication Operations & Sales by Region

(Billions of Yen)

	March 2021(FY2020)				March 2022(FY2021)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E	YOY
Japan*	27.0	60.6	92.4	123.0	28.9	62.8	+3.7%	131.3	+6.8%
<i>Lipovitan</i> series	10.4	24.4	35.9	45.8	11.8	26.2	+7.3%	49.0	+6.9%
<i>Pabron</i> series	3.5	9.1	15.6	21.1	3.5	9.4	+3.4%	22.0	+4.1%
<i>RiUP</i> series	3.5	7.6	11.7	14.9	3.5	7.0	-8.1%	15.3	+2.9%
<i>Biofermin</i> series	2.4	4.9	7.4	9.8	2.5	5.3	+8.9%	10.3	+5.9%
<i>NARON</i> series	0.8	1.6	2.2	3.0	0.9	2.0	+26.2%	3.5	+14.8%
GI treatment series	0.8	1.6	2.5	3.4	0.8	1.6	+2.6%	3.5	+3.0%
<i>VICKS</i> series	0.5	1.4	2.5	3.1	0.5	1.2	-9.5%	3.5	+11.4%
<i>Livita</i> series	0.8	1.5	2.4	3.2	0.8	1.5	-1.8%	3.2	+0.7%
<i>Colac</i> series	0.8	1.5	2.4	3.1	0.7	1.5	-1.7%	3.1	-1.9%
Overseas*	26.7	47.1	67.2	91.7	24.3	46.7	-0.8%	98.0	+6.9%
Asia	11.5	19.6	29.2	41.6	12.0	24.0	+22.2%	46.1	+10.8%
Europe and America	15.0	27.2	37.6	49.7	12.1	22.5	-17.4%	50.9	+2.5%
Others*	0.5	1.2	1.9	2.4	0.5	1.0	-14.6%	1.8	-24.4%

(Rounded to the nearest hundred-million)

* Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

** The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2021(FY2020)				March 2022(FY2021)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E	YOY
<i>Lipovitan</i> series	10.4	24.4	35.9	45.8	11.8	26.2	+7.3%	49.0	+6.9%
<i>Lipovitan D</i>	6.9	15.9	23.0	28.7	7.3	16.4	+3.1%	29.9	+4.1%
Others	3.5	8.5	12.8	17.1	4.5	9.8	+15.2%	19.1	+11.6%

(Rounded to the nearest hundred-million)

* Figures were obtained after application of the accounting standard for revenue recognition for both the fiscal year ending March 31, 2021 and that ending March 31, 2022.

Consolidated Sales - Leading Brands of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 2021(FY2020)				March 2022(FY2021)					
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	YOY	Full year E (New)	YOY	Full year E (Previous)
<i>Lusefi</i>	2.6	5.2	8.3	10.8	3.1	6.2	+18.1%	12.8	+18.5%	14.0
<i>Bonviva</i>	1.7	3.4	5.3	6.9	1.8	3.6	+7.6%	7.4	+7.4%	7.1
<i>LOQOA</i>	0.9	1.9	3.0	3.8	1.0	1.9	-1.2%	4.1	+7.7%	4.5
<i>Biofermin</i>	1.1	1.8	2.5	3.4	1.1	2.2	+19.4%	4.5	+32.4%	4.5
<i>Clarith</i>	0.5	1.0	1.8	2.2	0.5	1.0	+0.1%	2.1	-4.0%	1.9
<i>Palux</i>	0.6	1.2	1.9	2.4	0.6	1.1	-7.9%	2.1	-11.8%	1.9
<i>Geninax</i>	1.8	2.2	2.2	2.2	-	-	-100.0%	0.4	-81.8%	1.0

(Rounded to the nearest hundred-million)

* The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

Consolidated: Capital Expenditure

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Total capital expenditure	2,659	5,701	8,182	15,121	1,779	7,749	17,600
Taisho Pharmaceutical	1,081	3,258	5,170	7,793	1,316	4,097	10,350
Production department	358	652	904	1,379	269	656	1,210
Research department	37	764	1,013	1,519	8	1,589	5,540
Head Office and the others	684	1,841	3,252	4,894	1,039	1,851	3,600
Other subsidiaries	1,578	2,443	3,012	7,327	462	3,652	7,250

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Depreciation and amortization	3,673	7,206	10,925	14,700	3,508	7,347	14,000
Cost of sales	1,393	2,687	4,082	5,278	1,280	2,621	4,700
SGA expenses	2,280	4,519	6,843	9,421	2,228	4,725	9,300

Consolidated: R&D Expenses

(Millions of yen)

	March 2021(FY2020)				March 2022(FY2021)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q (4-9)	Full year E
Total R&D expenses	4,209	9,429	14,354	20,251	4,629	9,673	21,600
Self-Medication operations	1,578	3,469	5,374	7,492	1,952	4,013	7,900
Prescription Pharmaceutical operations	2,630	5,960	8,980	12,758	2,677	5,660	13,700

Major Subsidiaries and Affiliates

(As of September 30, 2021)

Company	Address	Capital	Business	Ownership*
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co., Ltd.	Tokyo, Japan	,000 Yen 29,837,892	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co., Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co., Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co., Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	100.0**
Taisho Pharma Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	PD	100.0
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co., Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co., Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co., Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 10,000	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,365	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 1,307,460,710	SMG	51.0
UPSA SAS	France	,000 EUR 852,103	SMG	100.0
UPSA Switzerland A.G.	Switzerland	,000 CHF 100	SMG	100.0
UPSA Italy S.r.l.	Italia	,000 EUR 10	SMG	100.0
UPSA Belgium S.A.	Belgium	,000 EUR 62	SMG	100.0
(2) Equity accounting method				
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.0

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

* Ownership: including the portion of indirect ownership

** Shares were exchanged to become a subsidiary fully owned by Taisho Pharmaceutical Holdings Co., Ltd. on July 30, 2021.

Major Shareholders (As of end of September 2021)

Major Shareholders

(Thousands of Shares)

Shareholder	Number of shares	% of total
The Uehara Memorial Foundation	15,000	18.28%
Shoji Uehara	7,734	9.43%
The Master Trust Bank of Japan, Ltd. (Trust account)	6,064	7.39%
Uehara Museum	3,900	4.75%
Sumitomo Mitsui Banking Corp.	3,000	3.66%
MUFG Bank, Ltd.	3,000	3.66%
Akira Uehara	2,143	2.61%
Custody Bank of Japan, Ltd. (Trust account)	1,698	2.07%
Kajima Corporation	1,650	2.01%
Custody Bank of Japan, Ltd. (Sumitomo Mitsui Trust Bank, Limited ReTrust Account/ Sumitomo Chemical Company, Limited Employee Pension Trust Account)	1,530	1.86%

Shares less than one thousand are rounded down.

Treasury stock of 3,083 thousand shares are excluded from the above as these shares do not have voting rights.

The shareholding ratio is calculated excluding treasury stock. (Rounded to the nearest second decimal place)

Distribution of Ownership Among Shareholders

	% of total
Financial Institutions	22.15%
Financial Instruments Firms	0.88%
Other companies	36.61%
Foreign Companies	13.98%
Individuals and Others	26.38%
Total	100.00%

The shareholder composition is calculated excluding treasury stock of 3,083 thousand shares.

(Rounded to the nearest second decimal place)

Prescription Pharmaceutical Operations:

New Drug Development - Taisho Pharmaceutical

As of November 9 , 2021

In Japan

Filed

Lusefi (Oral)

< Application	> Type2 diabetes
< Development	> In-house
< Description	> SGLT2 (Sodium-Glucose Cotransporter2) inhibitor
< Remarks	> Generic name: Luseogliflozin Hydrate Product name: Lusefi® Orally disintegrating film drug (drug form added)

TS-152 (Injection)

< Application	> Articular rheumatism against which existing therapies have insufficient efficacy
< Development	> In-license (Licensor: Ablynx)
< Description	> Anti-TNF(Tumor Necrosis Factor)-α antibody
< Remarks	> Generic name: Ozoralizumab

Phase 3

TS-071(Oral)

< Application	> Type2 diabetes (Pediatric)
< Development	> In-house
< Description	> SGLT2 (Sodium-Glucose Cotransporter2) inhibitor
< Remarks	> Generic name: Luseogliflozin Hydrate Product name: Lusefi®

Phase 2

TS-142 (Oral)

< Application	> Insomnia
< Development	> In-house

Phase 1

TS-172 (Oral)

< Application	> Hyperphosphatemia
< Development	> In-house

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of November 9 , 2021

Overseas

Phase 2

TS-161 (Oral)

< Target disease > Depression

< In-house/Licensed-in > In-house

Phase 1

TS-134 (Oral)

< Target disease > Schizophrenia

< In-house/Licensed-in > In-house

TS-142 (Oral)

< Target disease > Insomnia

< In-house/Licensed-in > In-house

Launch of New Products

As of November 9, 2021

New Products Since FY2021 1Q Earnings Announcement (August 5, 2021)

Self-Medication Operations

VICKS Medical Troche

- < Description > The medicated lozenge has a clean and refreshing taste with an elegant matcha flavor that suppresses its sweetness. The three active ingredients comprehensively act on the throat to reduce the pain and raspy voice caused by inflammation. The product helps discharge phlegm the throat and relieves annoying coughs.
- < Launch > September 2021

Sustained Release Pabron Tablets

- < Description > The cold remedy eases heavy cold symptoms. Use twice a day, morning and evening. This is the first successful example of an OTC combination cold remedy that enables the continuing effect of both analgesic antipyretic and expectorant ingredients. The lozenge includes a quick-melting coating using hydrophobic nano-coating technology and a slow-melting layer using the matrix drug system for controlled release. The remedy is long-lasting due to the formulation of the lozenge which enables the different ingredients to produce effects at different times.
- < Launch > September 2021

PABRON 50 TABLETS

- < Description > The cold remedy contains both crude drug extracts and Western medicine to ensure that it is highly effective. The formulation is free from antihistamines that cause drowsiness, dry mouth and hinder urination and dihydrocodeine phosphate which often causes constipation. The product has been redesigned with a new package that clearly displays the product's characteristics.
- < Launch > September 2021

LOXOPROFEN T Liquid

- < Description > The liquid analgesic antipyretic drug contains loxoprofen sodium hydrate. There is no need of cold or warm water when using the product. You can take the product wherever and whenever you like. Conveniently, you can cut off one dose to carry with you.
- < Launch > September 2021

VICKS Refreshing And Not Too Sweet Throat Drops

- < Description > The unsweet cough drop contains two polyphenols: mint and green tea (food).* There is a long-lasting refreshing feeling from the fresh, cooling sensation of lime juice reaching the deep parts of the throat. *Compared to our previous products.
- < Launch > September 2021

Launch of New Products

As of November 9, 2021

New Products Since FY2021 1Q Earnings Announcement (August 5, 2021)

Self-Medication Operations

BLACK WOLF VOLUME UP SCALP SHMPOO
 BLACK WOLF VOLUME UP SCALP CONDITIONER
 BLACK WOLF REFRESH SCALP SHAMPOO
 BLACK WOLF REFRESH SCALP CONDITIONER
 BLACK WOLF SCALP ESSENCE
 BLACK WOLF PREMIUM SCALP SHAMPOO
 BLACK WOLF PREMIUM SCALP CONDITIONER
 BLACK WOLF PREMIUM SCALP ESSENCE
 BLACK WOLF HAIR COLOR TREATMENT NATURAL BLACK
 BLACK WOLF HAIR COLOR TREATMENT NATURAL BROWN

< Description > The new hair care brand has been launched. It is intended to treat existing black hair. The black hair treatment series consists of three items supporting the scalp environment: shampoo that removes scalp sebum with a thick, rich foam, conditioner that gives firmness and body to black hair, and scalp essence providing the scalp with moisture. You can choose items according to the desired finish from three types of shampoo and conditioner: the volume boosting line, the refreshing line, the premium line. A scalp essence and two types of coloring hair pack are also available.

< Launch > October 2021

IRIS BREAK

< Description > The eye drop meets the need of smartphone users who want to immediately treat their eyes tired from the hard use of smartphone. Boasting the greatest number of active ingredients in Japan, the product contains 12 active ingredients including neostigmine methylsulfate, an ingredient for improving focus.* Feel the strongest cooling sensation (in the IRIS series) which leaves behind an exhilarating feeling after use.

*The largest number of active ingredients permitted under The Standards for Marketing Approval of Ophthalmic Medicines

< Launch > October 2021

IRIS Refresh

< Description > The eye drop meets the needs of smartphone users who want to take good care of their eyes which are tired from heavy smartphone use. Boasting the greatest number of active ingredients in Japan, the product contains 12 active ingredients including neostigmine methylsulfate, an ingredient for improving focus.* You can feel a lasting cooling sensation after use.

*The largest number of active ingredients permitted under The Standards for Marketing Approval of Ophthalmic Medicines

< Launch > October 2021

Launch of New Products

As of November 9, 2021

New Products Since FY2021 1Q Earnings Announcement (August 5, 2021)

Self-Medication Operations

Lipovitan D:Featuring Astronaut

< Description > Five Space Brothers-themed bottles bear illustrations from the manga. The bottles are put in a special ten-pack package box with a scene from the selection exam in Space Brothers printed on it.

< Launch > October 2021

RiUP EX JET

< Description > RiUP JET is a hair tonic for hair growth containing ingredients that condition the scalp environment and the new hair growth ingredient minoxidil. The active ingredient minoxidil normalizes the disturbed and shortened cycle of hair growth to prevent hair loss during periods of growth. It brings the original Fresh Pear scent and a refreshing feeling from cold jet.* Two scents are available, including RiUP JET, the subtly scented product launched in 2012. *Fresh Pear is a pear scent that is refreshing and fresh

< Launch > October 2021

Lipovitan D:Limited bottle to commemorate the team's victory

< Description > The bottle is available in the limited quantities, as it was designed to celebrate the ORIX Buffaloes becoming the 2021 Pacific League champions. To be distributed by reservation sale via the Taisho Pharmaceutical Direct online store.

< Launch > October 2021

Lipovitan D:Christmas bottle 2021

< Description > Two bottles themed on snowy nights are available in limited quantities. The red Tree Bottle shows a couple meeting in front of a Christmas tree. The green Snowman Bottle shows children making a snowman. To be distributed by reservation sale via the Taisho Pharmaceutical Direct online store.

< Launch > November 2021
